Clinical Trials Browser

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Clinical Trials

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

ARASTEP

ANDARP

STRIKE-001

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

ARAMON

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

CHINANEO

TulmiSTAR-02

ARANOTE

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

AMX-500

SOGUG-PRINCIS

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Double-DARE

COAction

ARASEC

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

ROAD

EvoPAR-PR01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

ENGAGER-PSMA-01

TRIPLE-SWITCH

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

DIVINE

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

PRO-MIND

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

ARACOG

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Prostate Cancer Biomarker Enrichment and Treatment Selection

DECREASE

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Study to Evaluate CCS1477 in Advanced Tumours

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

DEAR-EXT

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)